Table 1 Clinicopathological features of the patients included in the differential expression analyses
Characteristics | HBC | SBC | NBT | |||
|---|---|---|---|---|---|---|
BRCA1 | BRCA2 | BRCAX | n = 23 | BRCA1/2 | WT | |
n = 15 | n = 14 | n = 14 | n = 5 | n = 3 | ||
Clinical | ||||||
Age at diagnosis, y | ||||||
Mean (SD) | 43.73 (8.30) | 44.57 (11.18) | 41.78 (12.14) | 48.73 (10.45) | 41.80 (5.89) | 58.00 (9.16) |
Range | 29–59 | 26–67 | 25–66 | 30–77 | 35–51 | 50–68 |
Pathological, n (%) | ||||||
Grade (SBR)* | ||||||
.. .1 | 1 (6,7) | 0 | 1 (7.1) | 0 | ||
.. .2 | 4 (26.7) | 5 (35.7) | 6 (42.9) | 3 (13) | ||
... 3 | 10 (66.7) | 9 (64.3) | 7 (50) | 20 (87) | ||
ER* | ||||||
Negative | 12 (80) | 4 (28.6) | 5 (35.7) | 17 (73.9) | ||
Positive | 3 (20) | 10 (71.4) | 9 (64.3) | 6 (26.1) | ||
PR* | ||||||
Negative | 11 (73.3) | 6 (42.9) | 7 (50) | 19 (82,6) | ||
Positive | 4 (26.7) | 8 (57.1) | 7 (50) | 4 (17.4) | ||
HER2 amplification* | ||||||
Negative | 14 (93.3) | 12 (85.7) | 11 (78.6) | 19 (82,6) | ||
Positive | 1 (6.7) | 2 (14.3) | 3 (21.4) | 4 (17.4) | ||
Molecular subtype* | ||||||
Luminal | 4 (26.7) | 11 (78.6) | 9 (64.3) | 6 (26.1) | ||
HER2+ | 0 | 0 | 2 (14.3) | 1 (4.3) | ||
Triple-negative | 11 (73.3) | 3 (21.4) | 4 (21.4) | 16 (69.6) | ||
TNM* | ||||||
I | 2 (13.3) | 0 | 3 (21.4) | 1 (4.3) | ||
II | 9 (60) | 4 (28.6) | 9 (64.3) | 11 (47.8) | ||
III | 3 (20) | 8 (57.1) | 1 (7.1) | 10 (43.5) | ||
IV | 1 (6.7) | 2 (14.3) | 1 (7.1) | 1 (4.3) | ||